JP2014510746A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014510746A5 JP2014510746A5 JP2014501719A JP2014501719A JP2014510746A5 JP 2014510746 A5 JP2014510746 A5 JP 2014510746A5 JP 2014501719 A JP2014501719 A JP 2014501719A JP 2014501719 A JP2014501719 A JP 2014501719A JP 2014510746 A5 JP2014510746 A5 JP 2014510746A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- compound according
- pharmaceutical composition
- hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000031886 HIV Infections Diseases 0.000 claims description 3
- 208000037357 HIV infectious disease Diseases 0.000 claims description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 229930194542 Keto Natural products 0.000 claims 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- -1 aldehyde macrocycle Chemical class 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002829 reductive effect Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000000134 cyclophilin inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000023611 glucuronidation Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930185087 sanglifehrin Natural products 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OLROWHGDTNFZBH-XEMWPYQTSA-N Alisporivir Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O OLROWHGDTNFZBH-XEMWPYQTSA-N 0.000 description 1
- LBKDOKHAKPIWCL-NSVPLCITSA-N CC(C)[C@@H](C(N[C@](C1)(C1C(CC(O)=C1)C=C1F)C(N(CCC1)N[C@@H]1C(O[C@@H](C/C=C/C=C/[C@@H]([C@H](C)[C@H]([C@H]1CCC(C)=O)O)O)/C(/C)=C/C=O)=O)=O)=O)NC1=O Chemical compound CC(C)[C@@H](C(N[C@](C1)(C1C(CC(O)=C1)C=C1F)C(N(CCC1)N[C@@H]1C(O[C@@H](C/C=C/C=C/[C@@H]([C@H](C)[C@H]([C@H]1CCC(C)=O)O)O)/C(/C)=C/C=O)=O)=O)=O)NC1=O LBKDOKHAKPIWCL-NSVPLCITSA-N 0.000 description 1
- 102000001493 Cyclophilins Human genes 0.000 description 1
- 108010068682 Cyclophilins Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010058359 alisporivir Proteins 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1105293.3A GB201105293D0 (en) | 2011-03-29 | 2011-03-29 | Novel compounds and methods for their production |
| GB1105293.3 | 2011-03-29 | ||
| GB1113629.8 | 2011-08-08 | ||
| GBGB1113629.8A GB201113629D0 (en) | 2011-08-08 | 2011-08-08 | Novel compounds and methods for their production |
| GBGB1202060.8A GB201202060D0 (en) | 2012-02-07 | 2012-02-07 | Novel compounds and methods for their production |
| GB1202060.8 | 2012-02-07 | ||
| PCT/GB2012/050700 WO2012131371A1 (en) | 2011-03-29 | 2012-03-29 | Macrocyclic compound and methods for its production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014510746A JP2014510746A (ja) | 2014-05-01 |
| JP2014510746A5 true JP2014510746A5 (OSRAM) | 2015-05-14 |
| JP6118792B2 JP6118792B2 (ja) | 2017-04-26 |
Family
ID=46001313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501719A Expired - Fee Related JP6118792B2 (ja) | 2011-03-29 | 2012-03-29 | マクロ環状化合物及びその製造方法 |
| JP2014501720A Active JP6118793B2 (ja) | 2011-03-29 | 2012-03-29 | マクロ環状化合物及びそれらの製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014501720A Active JP6118793B2 (ja) | 2011-03-29 | 2012-03-29 | マクロ環状化合物及びそれらの製造方法 |
Country Status (29)
| Country | Link |
|---|---|
| US (2) | US9090657B2 (OSRAM) |
| EP (2) | EP2691412B1 (OSRAM) |
| JP (2) | JP6118792B2 (OSRAM) |
| KR (2) | KR101868084B1 (OSRAM) |
| CN (3) | CN103619869B (OSRAM) |
| AR (1) | AR085724A1 (OSRAM) |
| AU (2) | AU2012235880B2 (OSRAM) |
| BR (2) | BR112013024974A2 (OSRAM) |
| CA (2) | CA2830831C (OSRAM) |
| CL (2) | CL2013002739A1 (OSRAM) |
| CY (2) | CY1116318T1 (OSRAM) |
| DK (2) | DK2691413T3 (OSRAM) |
| EA (2) | EA023848B1 (OSRAM) |
| ES (2) | ES2533438T3 (OSRAM) |
| HR (2) | HRP20150187T1 (OSRAM) |
| IL (2) | IL228509B (OSRAM) |
| JO (1) | JO3063B1 (OSRAM) |
| MX (2) | MX345351B (OSRAM) |
| MY (2) | MY170637A (OSRAM) |
| PH (2) | PH12013502000B1 (OSRAM) |
| PL (2) | PL2691412T3 (OSRAM) |
| PT (2) | PT2691412E (OSRAM) |
| RS (2) | RS53963B1 (OSRAM) |
| SG (2) | SG193568A1 (OSRAM) |
| SI (2) | SI2691413T1 (OSRAM) |
| TW (1) | TWI525098B (OSRAM) |
| UY (1) | UY33993A (OSRAM) |
| WO (2) | WO2012131371A1 (OSRAM) |
| ZA (2) | ZA201307149B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012019866A8 (pt) | 2010-02-09 | 2017-12-26 | Biotica Tech Limited | Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
| CN103130734A (zh) * | 2011-12-01 | 2013-06-05 | 上海药明康德新药开发有限公司 | 一种合成1,2-吗啉盐酸盐的方法 |
| CN105695541B (zh) * | 2016-03-10 | 2019-03-15 | 苏州华赛生物工程技术有限公司 | 一种抗生素nvp018中间体的分离纯化方法 |
| KR20180036522A (ko) * | 2016-09-30 | 2018-04-09 | (주)나노믹스 | 스틸벤 유도체 및 그 제조 방법 |
| JP2019535726A (ja) * | 2016-11-18 | 2019-12-12 | ネウロビベ プハルマセウトイカル エービー | サングリフェリンマクロ環状類似体の抗がん化合物としての使用 |
| CN112410353B (zh) * | 2019-08-23 | 2023-01-24 | 上海医药工业研究院 | 一种fkbS基因、含其的基因工程菌及其制备方法和用途 |
| CA3159561A1 (en) | 2019-11-04 | 2021-05-14 | Revolution Medicines, Inc. | Ras inhibitors |
| PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
| PE20240089A1 (es) | 2021-05-05 | 2024-01-16 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cancer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN115028681B (zh) * | 2022-08-11 | 2022-11-15 | 中国科学院微生物研究所 | 一种降解亲环素a的嵌合体化合物及其制备方法与应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| WO2006138507A1 (en) | 2005-06-17 | 2006-12-28 | Novartis Ag | Use of sanglifehrin in hcv |
| BRPI0806265A2 (pt) | 2007-01-04 | 2011-09-06 | Debiopharm Sa | ciclosporina não-imunossupressora para tratamento de distrofia muscular congênita de ullrich |
| CN101691575B (zh) * | 2008-09-24 | 2013-06-05 | 中国科学院上海有机化学研究所 | 一种萨菲菌素的生物合成基因簇 |
| US8962329B2 (en) | 2008-09-24 | 2015-02-24 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Gene cluster |
| BR112012019866A8 (pt) * | 2010-02-09 | 2017-12-26 | Biotica Tech Limited | Composto, uso do mesmo, composição farmacêutica, e, processo para preparar um composto |
| WO2011098808A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| WO2011098805A1 (en) * | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Sanglifehrin based compounds |
| CN107090476B (zh) * | 2010-12-20 | 2021-09-24 | 爱博利瓦有限公司 | Sanglifehrin衍生物及其制备方法 |
| JO3063B1 (ar) * | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
-
2012
- 2012-03-12 JO JOP/2012/0053A patent/JO3063B1/ar active
- 2012-03-28 AR ARP120101043A patent/AR085724A1/es unknown
- 2012-03-28 TW TW101110673A patent/TWI525098B/zh not_active IP Right Cessation
- 2012-03-29 KR KR1020137027773A patent/KR101868084B1/ko not_active Expired - Fee Related
- 2012-03-29 RS RS20150161A patent/RS53963B1/sr unknown
- 2012-03-29 CA CA2830831A patent/CA2830831C/en not_active Expired - Fee Related
- 2012-03-29 WO PCT/GB2012/050700 patent/WO2012131371A1/en not_active Ceased
- 2012-03-29 EP EP12716538.9A patent/EP2691412B1/en active Active
- 2012-03-29 AU AU2012235880A patent/AU2012235880B2/en not_active Ceased
- 2012-03-29 PH PH1/2013/502000A patent/PH12013502000B1/en unknown
- 2012-03-29 EP EP12716539.7A patent/EP2691413B1/en active Active
- 2012-03-29 RS RS20150162A patent/RS53964B1/sr unknown
- 2012-03-29 US US13/433,944 patent/US9090657B2/en active Active
- 2012-03-29 AU AU2012235961A patent/AU2012235961B2/en not_active Ceased
- 2012-03-29 BR BR112013024974A patent/BR112013024974A2/pt not_active Application Discontinuation
- 2012-03-29 EA EA201391399A patent/EA023848B1/ru not_active IP Right Cessation
- 2012-03-29 ES ES12716539.7T patent/ES2533438T3/es active Active
- 2012-03-29 ES ES12716538.9T patent/ES2533437T3/es active Active
- 2012-03-29 PL PL12716538T patent/PL2691412T3/pl unknown
- 2012-03-29 CN CN201280026190.3A patent/CN103619869B/zh not_active Expired - Fee Related
- 2012-03-29 CN CN201611126823.4A patent/CN107417766A/zh active Pending
- 2012-03-29 MY MYPI2013701788A patent/MY170637A/en unknown
- 2012-03-29 SI SI201230146T patent/SI2691413T1/sl unknown
- 2012-03-29 US US14/006,341 patent/US9139613B2/en active Active
- 2012-03-29 PT PT127165389T patent/PT2691412E/pt unknown
- 2012-03-29 UY UY0001033993A patent/UY33993A/es not_active Application Discontinuation
- 2012-03-29 SG SG2013070966A patent/SG193568A1/en unknown
- 2012-03-29 KR KR1020137028095A patent/KR101911484B1/ko not_active Expired - Fee Related
- 2012-03-29 PH PH1/2013/502016A patent/PH12013502016A1/en unknown
- 2012-03-29 SI SI201230145T patent/SI2691412T1/sl unknown
- 2012-03-29 PL PL12716539T patent/PL2691413T3/pl unknown
- 2012-03-29 DK DK12716539T patent/DK2691413T3/en active
- 2012-03-29 SG SG2013070974A patent/SG193569A1/en unknown
- 2012-03-29 EA EA201391396A patent/EA023907B1/ru not_active IP Right Cessation
- 2012-03-29 BR BR112013024965A patent/BR112013024965A2/pt not_active Application Discontinuation
- 2012-03-29 DK DK12716538T patent/DK2691412T3/en active
- 2012-03-29 MY MYPI2013701789A patent/MY170618A/en unknown
- 2012-03-29 WO PCT/GB2012/050707 patent/WO2012131377A1/en not_active Ceased
- 2012-03-29 JP JP2014501719A patent/JP6118792B2/ja not_active Expired - Fee Related
- 2012-03-29 CA CA2830827A patent/CA2830827C/en not_active Expired - Fee Related
- 2012-03-29 HR HRP20150187TT patent/HRP20150187T1/hr unknown
- 2012-03-29 JP JP2014501720A patent/JP6118793B2/ja active Active
- 2012-03-29 MX MX2013011043A patent/MX345351B/es active IP Right Grant
- 2012-03-29 PT PT127165397T patent/PT2691413E/pt unknown
- 2012-03-29 CN CN201280026793.3A patent/CN103635484B/zh active Active
- 2012-03-29 HR HRP20150184TT patent/HRP20150184T1/hr unknown
- 2012-03-29 MX MX2013011051A patent/MX345352B/es active IP Right Grant
-
2013
- 2013-09-17 IL IL228509A patent/IL228509B/en active IP Right Grant
- 2013-09-17 IL IL228508A patent/IL228508B/en active IP Right Grant
- 2013-09-23 ZA ZA2013/07149A patent/ZA201307149B/en unknown
- 2013-09-25 CL CL2013002739A patent/CL2013002739A1/es unknown
- 2013-09-25 CL CL2013002740A patent/CL2013002740A1/es unknown
- 2013-09-26 ZA ZA2013/07231A patent/ZA201307231B/en unknown
-
2015
- 2015-02-27 CY CY20151100207T patent/CY1116318T1/el unknown
- 2015-03-06 CY CY20151100236T patent/CY1116186T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014510746A5 (OSRAM) | ||
| EP3527573B9 (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
| JP2010523522A5 (OSRAM) | ||
| JP2017527589A (ja) | 新規なアミノアルキルベンゾチアゼピン誘導体及びその用途 | |
| JP2015536940A (ja) | 抗ウイルス性ホスホネート類似体及びその製造方法 | |
| HRP20150184T1 (hr) | Makrocikliäśki spoj i postupci za njegovu proizvodnju | |
| JP2013518923A5 (OSRAM) | ||
| EP2321323B9 (fr) | Derives dimeriques d'artemisinine et application en therapie anticancereuse | |
| WO2007013086A1 (en) | Novel polymorphs of tenofovir disoproxil fumarate | |
| CN115135646B (zh) | 取代的多环化合物及其药物组合物和用途 | |
| WO2009074020A1 (fr) | Amides n-substitués par alpha-amino, composition pharmaceutique les contenant et leurs utilisations | |
| JP2009143931A (ja) | テトラゾリルベンゾピランの製法 | |
| CA2647163C (en) | Modified macrophage migration inhibitory factor inhibitors | |
| WO2016038560A1 (en) | Process for the preparation of enzalutamide | |
| RU2010134904A (ru) | Кристаллическая форма абакавира, которая, по существу, свободна от растворителя | |
| CN120424092B (zh) | 布尼亚病毒抑制剂及其制备方法和用途 | |
| JP5863846B2 (ja) | イリノテカンの製造方法 | |
| CN111417632A (zh) | 噻唑-5-甲酸衍生物及其制备方法与应用 | |
| CN110590768B (zh) | 杂环化合物、其组合物及其作为抗流感病毒药物的应用 | |
| WO2017009746A1 (en) | An improved process for the preparation of sofosbuvir | |
| Ye et al. | Studies on the asymmetric synthesis of pandamarilactonines: an unexpected syn-selective vinylogous Mannich reaction of N-tert-butanesulfinimines | |
| Therkelsen et al. | New emivirine (MKC-442) analogues containing a tetrahydronaphthalene at C-6 and their anti-HIV activity | |
| CN120574228A (zh) | 取代的多环吡啶酮类衍生物及其制备方法和用途 | |
| CZ2014792A3 (cs) | Způsob přípravy, izolace a čištění farmaceuticky využitelných forem AHU-377 | |
| HK40011503B (en) | Synthesis of polycyclic-carbamoylpyridone compounds |